212 related articles for article (PubMed ID: 15657183)
1. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias.
Nowbakht P; Ionescu MC; Rohner A; Kalberer CP; Rossy E; Mori L; Cosman D; De Libero G; Wodnar-Filipowicz A
Blood; 2005 May; 105(9):3615-22. PubMed ID: 15657183
[TBL] [Abstract][Full Text] [Related]
2.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
3. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.
Sanchez-Correa B; Morgado S; Gayoso I; Bergua JM; Casado JG; Arcos MJ; Bengochea ML; Duran E; Solana R; Tarazona R
Cancer Immunol Immunother; 2011 Aug; 60(8):1195-205. PubMed ID: 21644031
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer.
Peipp M; Klausz K; Boje AS; Zeller T; Zielonka S; Kellner C
Clin Exp Immunol; 2022 Jul; 209(1):22-32. PubMed ID: 35325068
[TBL] [Abstract][Full Text] [Related]
5. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells.
Pende D; Parolini S; Pessino A; Sivori S; Augugliaro R; Morelli L; Marcenaro E; Accame L; Malaspina A; Biassoni R; Bottino C; Moretta L; Moretta A
J Exp Med; 1999 Nov; 190(10):1505-16. PubMed ID: 10562324
[TBL] [Abstract][Full Text] [Related]
6. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation.
Sivori S; Falco M; Marcenaro E; Parolini S; Biassoni R; Bottino C; Moretta L; Moretta A
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4526-31. PubMed ID: 11917118
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression.
Kim N; Yi E; Lee E; Park HJ; Kim HS
Front Immunol; 2024; 15():1388018. PubMed ID: 38698855
[TBL] [Abstract][Full Text] [Related]
8. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.
Epling-Burnette PK; Bai F; Painter JS; Rollison DE; Salih HR; Krusch M; Zou J; Ku E; Zhong B; Boulware D; Moscinski L; Wei S; Djeu JY; List AF
Blood; 2007 Jun; 109(11):4816-24. PubMed ID: 17341666
[TBL] [Abstract][Full Text] [Related]
9. Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells.
von Lilienfeld-Toal M; Nattermann J; Feldmann G; Sievers E; Frank S; Strehl J; Schmidt-Wolf IG
Clin Exp Immunol; 2006 Jun; 144(3):528-33. PubMed ID: 16734623
[TBL] [Abstract][Full Text] [Related]
10. The Natural Cytotoxicity Receptor NKp44 (NCR2, CD336) Is Expressed on the Majority of Porcine NK Cells
Mair KH; Crossman AJ; Wagner B; Babasyan S; Noronha L; Boyd P; Zarlenga D; Stadler M; van Dongen KA; Gerner W; Saalmüller A; Lunney JK
Front Immunol; 2022; 13():767530. PubMed ID: 35154097
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer activity and mechanistic features of a NK cell activating molecule.
Kim HR; Lee KH; Park SJ; Kim SY; Yang YK; Tae J; Kim J
Cancer Immunol Immunother; 2009 Oct; 58(10):1691-700. PubMed ID: 19259669
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cells control metastasis via structural editing of primary tumors in mice.
Isaacson B; Mandelboim O
Cancer Immunol Immunother; 2019 Oct; 68(10):1721-1724. PubMed ID: 31606778
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?
Sanchez-Correa B; Campos C; Pera A; Bergua JM; Arcos MJ; Bañas H; Casado JG; Morgado S; Duran E; Solana R; Tarazona R
Cancer Immunol Immunother; 2016 Apr; 65(4):453-63. PubMed ID: 26059279
[TBL] [Abstract][Full Text] [Related]
14. Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia.
Hussein BA; Hallner A; Wennström L; Brune M; Martner A; Hellstrand K; Bernson E; Thorén FB
Front Immunol; 2021; 12():796072. PubMed ID: 34956230
[TBL] [Abstract][Full Text] [Related]
15. Elevated levels of cell-free NKG2D-ligands modulate NKG2D surface expression and compromise NK cell function in severe COVID-19 disease.
Fernández-Soto D; García-Jiménez ÁF; Casasnovas JM; Valés-Gómez M; Reyburn HT
Front Immunol; 2024; 15():1273942. PubMed ID: 38410511
[TBL] [Abstract][Full Text] [Related]
16. Largely preserved functionality after the combined loss of NKG2D, NCR1 and CD16 demonstrates the remarkable plasticity of NK cell responsiveness.
Imširović V; Lenartić M; Wensveen FM; Polić B; Jelenčić V
Front Immunol; 2023; 14():1191884. PubMed ID: 37520575
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell-mimic nanoparticles can actively target and kill acute myeloid leukemia cells.
Alizadeh Zeinabad H; Yeoh WJ; Arif M; Lomora M; Banz Y; Riether C; Krebs P; Szegezdi E
Biomaterials; 2023 Jul; 298():122126. PubMed ID: 37094524
[TBL] [Abstract][Full Text] [Related]
18. Reduced Expression of Natural Killer Cell-Related Activating Receptors by Peripheral Blood Mononuclear Cells from Patients with Breast Cancer and Their Improvement by Zoledronic Acid.
Rahimian L; Kalantari Khandani B; Nemati M; Hoseini-Shahrestanak S; Aminizadeh N; Jafarzadeh A
Asian Pac J Cancer Prev; 2022 May; 23(5):1661-1669. PubMed ID: 35633551
[TBL] [Abstract][Full Text] [Related]
19. The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands.
Maurer S; Zhong X; Prada BD; Mascarenhas J; de Andrade LF
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555547
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT/CD155 pathway.
Yue J; Li J; Ma J; Zhai Y; Shen L; Zhang W; Li L; Fu R
Hematology; 2023 Dec; 28(1):2166333. PubMed ID: 36651499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
